Verastem Oncology Reports Promising Early Data for Pancreatic Cancer Combo Therapy
Event summary
- Verastem Oncology reported updated Phase 1b/2a trial results showing 86% 6-month overall survival rate for avutometinib + defactinib combo in metastatic pancreatic cancer.
- The RAMP 205 trial enrolled 29 patients, with 52% achieving confirmed objective response rate and 83% experiencing tumor shrinkage.
- PanCAN awarded Verastem $3.8M in 2022 to support this research through its Therapeutic Accelerator Award.
- The combination therapy demonstrated manageable safety profile consistent with prior reports, with no new safety signals observed.
The big picture
Verastem's positive RAMP 205 results represent a potential breakthrough in treating KRAS-mutated pancreatic cancer, which accounts for over 90% of cases. The combination therapy targets both KRAS-driven signaling and FAK-mediated resistance pathways, addressing a critical unmet need in a disease with poor survival rates. This development comes as Verastem continues to expand its portfolio of RAS/MAPK pathway inhibitors, following its 2025 FDA approval for a similar combination in low-grade serous ovarian cancer.
What we're watching
- Clinical Validation
- Whether the maturing overall survival data will confirm the early promising trends observed in the RAMP 205 trial.
- Regulatory Pathway
- The pace at which Verastem can advance this combination therapy through subsequent clinical trials and potential regulatory approval.
- Strategic Partnerships
- How Verastem will leverage these results to pursue future collaborations or development opportunities in pancreatic cancer.
Related topics